Novel predictive approaches for drug-induced convulsions in non-human primates using machine learning and heart rate variability analysis.

Journal: The Journal of toxicological sciences
PMID:

Abstract

Drug-induced convulsions are a major challenge to drug development because of the lack of reliable biomarkers. Using machine learning, our previous research indicated the potential use of an index derived from heart rate variability (HRV) analysis in non-human primates as a biomarker for convulsions induced by GABA receptor antagonists. The present study aimed to explore the application of this methodology to other convulsants and evaluate its specificity by testing non-convulsants that affect the autonomic nervous system. Telemetry-implanted males were administered various convulsants (4-aminopyridine, bupropion, kainic acid, and ranolazine) at different doses. Electrocardiogram data gathered during the pre-dose period were employed as training data, and the convulsive potential was evaluated using HRV and multivariate statistical process control. Our findings show that the Q-statistic-derived convulsive index for 4-aminopyridine increased at doses lower than that of the convulsive dose. Increases were also observed for kainic acid and ranolazine at convulsive doses, whereas bupropion did not change the index up to the highest dose (1/3 of the convulsive dose). When the same analysis was applied to non-convulsants (atropine, atenolol, and clonidine), an increase in the index was noted. Thus, the index elevation appeared to correlate with or even predict alterations in autonomic nerve activity indices, implying that this method might be regarded as a sensitive index to fluctuations within the autonomic nervous system. Despite potential false positives, this methodology offers valuable insights into predicting drug-induced convulsions when the pharmacological profile is used to carefully choose a compound.

Authors

  • Kazuhiro Kuga
    Drug Safety Research and Evaluation, Takeda Pharmaceutical Company Ltd., Kanagawa, Japan.
  • Motohiro Shiotani
    Global drug safety, Eisai Co., Ltd.
  • Kentaro Hori
    Quadlytics Inc.
  • Hiroshi Mizuno
    Advanced Biosignal Safety Assessment, Eisai Co., Ltd.
  • Yusaku Matsushita
    Advanced Biosignal Safety Assessment, Eisai Co., Ltd.
  • Harushige Ozaki
    Drug Safety Research and Evaluation, Takeda Pharmaceutical Company Ltd., Kanagawa, Japan.
  • Kohei Hayashi
    Quadlytics Inc.
  • Takatomi Kubo
    Division of Information Science, Graduate School of Science and Technology, Nara Institute of Science and Technology, 8916-5 Takayama-Cho, Ikoma, Nara 630-0192, Japan. Electronic address: takatomi-k@is.naist.jp.
  • Manabu Kano
    Department of Systems Science, Kyoto University, Kyoto, Japan.